Buprenorphine

Major

Buprenorphine Trifluoperazine Explained An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Trifluperidol Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Triflupromazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Trihexyphenidyl Explained An increased risk of paralytic ileus Details Buprenorphine Trimeprazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Trimipramine Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Triptorelin Explained An increased risk of QT interval prolongation Details Buprenorphine Troleandomycin Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Tropicamide Mydriacyl Explained An increased risk of paralytic ileus Details Buprenorphine Trospium Explained An increased risk of paralytic ileus Details Buprenorphine Tryptophan Explained An increased risk of serotonin syndrome Details Buprenorphine Tucatinib Tukysa Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Umeclidinium Explained An increased risk of paralytic ileus Details Buprenorphine Vandetanib Caprelsa Explained An increased risk of QT interval prolongation Details Buprenorphine Vardenafil Levitra Explained An increased risk of QT interval prolongation Details Buprenorphine Vemurafenib Zelboraf Explained An increased risk of QT interval prolongation Details Buprenorphine Venlafaxine Explained An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Vepdegestrant Veppanu Explained An increased risk of QT interval prolongation and an increased risk of torsade de pointes, polymorphic ventricular tachycardia, ot... Details Buprenorphine Verapamil Calan Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Vilanterol Explained An increased risk of QT interval prolongation Details Buprenorphine Vilazodone Viibryd Explained An increased risk of serotonin syndrome Details Buprenorphine Vinflunine Explained An increased risk of QT interval prolongation Details Buprenorphine Voclosporin Lupkynis Explained An increased risk of QT interval prolongation Details Buprenorphine Voriconazole Vfend Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Vorinostat Zolinza Explained An increased risk of QT interval prolongation Details Buprenorphine Vortioxetine Trintellix Explained An increased risk of serotonin syndrome Details Buprenorphine Voxelotor Oxbryta Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Xipamide Explained Reduced efficacy of diuretics Details Buprenorphine Zaleplon Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Ziftomenib Komzifti Explained An increased risk of QT interval prolongation and torsade de pointes Details Buprenorphine Zolmitriptan Zomig Explained An increased risk of serotonin syndrome Details Buprenorphine Zolpidem Ambien Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Zopiclone Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Zotepine Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Zuclopenthixol Explained An increased risk of QT interval prolongation Details Buprenorphine Zuranolone Zurzuvae Explained An increased risk of CNS depression Details Buprenorphine Ethanol Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Trospium / Xanomeline Cobenfy Explained An increased risk of paralytic ileus Details Buprenorphine Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Buprenorphine Aripiprazole Injection Abilify An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details